pyrazines has been researched along with bezafibrate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noacco, C; Taboga, C; Tonutti, L | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Cummings, MH; Watts, GF | 1 |
| Mir, MA; Oleesky, DA | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Gujer, W; Neumann, MB; von Gunten, U | 1 |
1 trial(s) available for pyrazines and bezafibrate
| Article | Year |
|---|---|
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
5 other study(ies) available for pyrazines and bezafibrate
| Article | Year |
|---|---|
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
Topics: Adult; Bezafibrate; Cholesterol, HDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrazines | 1997 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |
Global sensitivity analysis for model-based prediction of oxidative micropollutant transformation during drinking water treatment.
Topics: Bezafibrate; Carcinogens; Ciprofloxacin; Methyl Ethers; Naphthols; Ozone; Predictive Value of Tests; Probability; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Water Pollutants, Chemical; Water Supply | 2009 |